The coffee diterpene kahweol is an antitumoral compound for human estrogen receptor-negative breast cancer cells

Miguel Ángel Medina Torres¹, Ana Rodríguez Quesada¹, Casimiro Cárdenas²
¹Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of Málaga.
CIBER de Enfermedades Raras (CIBERER), Málaga, ES, ²Department of Molecular Biology and Biochemistry, Faculty of Sciences, University of Málaga. Research Support Central Services (SCAI) of the University of Málaga, Málaga, ES

Although epidemiological studies indicate that coffee consumption is associated with a low incidence of several kinds of cancer, there are still few studies on the anti-tumoral effects of pure bioactive compounds isolated from coffee. The present study aims to identify the modulatory effects of kahweol, an antioxidant diterpene contained in unfiltered coffee, on a panel of human tumor cell lines. Kahweol inhibits tumor cell proliferation and clonogenicity and induces apoptosis in several kinds of human tumor cells, with a special incidence on the estrogen receptor-negative MDA-MB231 human breast cancer cells. In these breast cancer cells, the mentioned effects are accompanied by caspases 3/7 and 9 activation and cytochrome c release, both consistent with an activation of the intrinsic pathway of apoptosis. Kahweol also increases the phosphorylation levels of protein kinase B (AKT) and extracellular-signal-regulated kinase (ERK) observed in MDA-MB-231 cells. We also demonstrate the inhibitory effect of kahweol on the MDA-MB231 cell potential to migrate and to remodel extracellular matrix by targeting matrix metalloproteinase-9 and urokinase-type plasminogen activator, two key molecules involved in this process. Taken together, our data suggest that, indeed, kahweol behaves as an antitumor compound, especially against MDA-MB231 breast cancer cells.

Acknowledgements: Our experimental work was initially supported by grants PS09/02216 and PI12/01096 (Spanish Ministry of Economy and Competitiveness), and PIE P08-CTS-3759, CVI-6585 and funds from group BIO-267 (Andalusian Government). Currently, no active grant funds our research. The "CIBER de Enfermedades Raras" is an initiative from the ISCIII (Spain).